Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Depression
Interventions: TEAM-Red, Waitlist; Behavioral · Other
Lead sponsor: Jennifer B. Levin; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Blood Pressure, Hypertension, Elevated Blood Pressure, Sleep, Short Sleep Phenotype
Interventions: Sleep hygiene/extension intervention, Control care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: No Treatment; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Esophageal and Gastric Varices, Liver Cirrhosis
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Distal Splenorenal Shunt; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • Cleveland, Ohio + 2 more

Conditions: Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions: Sildenafil (50 mg); Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Natriuretic Peptides, Cardiovascular Diseases, Hypertension, Diabetes, Obesity
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Mobile, Alabama • Los Angeles, California • Pasadena, California + 11 more

Conditions: Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions: 2-hydroxybenzylamine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus
Interventions: Aliskiren + Valsartan; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma
Interventions: Collection of trabecular meshwork tissue during surgery; Other
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pre-Eclampsia
Interventions: StO2 and EndoPAT; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glaucoma, Ocular Hypertension
Interventions: BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Week to 5 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib mesylate, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Newark, New Jersey • New York, New York

Conditions: Cardiovascular Diseases, Hypertension, Racism, Vascular Diseases
Interventions: MitoQ; Dietary Supplement
Lead sponsor: Auburn University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Hypertension in Pregnancy
Interventions: Enalapril 10mg QD, Nifedipine 30mg XL BID; Drug
Lead sponsor: Nebraska Methodist Health System; Other
Eligibility: 19 Years and older · Female only
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Brain Care Score, Exercise, Hypertension, BMI
Interventions: Exercise Intervention to improve overall Brain Health; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 35 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Subarachnoid Hemorrhage, Hypertension
Interventions: Clevidipine butyrate injectable emulsion; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metabolic Syndrome
Interventions: 3-V Bioscience-2640; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 35 Years to 60 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Overweight, Obesity, Hypertension, Prehypertension, Anxiety, Well-being, Depression, Low Physical Fitness, Psychological
Interventions: Fit2Play curriculum; Other
Lead sponsor: Duke University; Other
Eligibility: 6 Years to 14 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension
Interventions: Health Education, Home Blood Pressure Monitor; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Mankato, Minnesota

Conditions: Cancer, Breast, Diabetes Mellitus, Hypertension, Cancer Prostate
Interventions: Support; Behavioral
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pre-Eclampsia
Interventions: Exercise Modes; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Preeclampsia
Interventions: Aspirin 81Mg Non-enteric coated Tab; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 13 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

TEAM-Red, a Remotely Delivered Self-management Program for Depressed Black Women at Risk for Hypertension

Sleep Duration and Blood Pressure During Sleep

Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Decompression Intervention of Variceal Rebleeding Trial (DIVERT)

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

CARBON: UAB Cardiovascular Research Biobank

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

Utilization of Somatic Tissue Oxygen Saturation Monitoring in Pregnant Women

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Mitochondria Oxidative Stress and Vascular Health Study

Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

An Exercise Intervention to Improve Overall Brain Health

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study

A Study of Cardiovascular Disparities in the Greater Mankato Somali Community to Prevent Hypertension

Comorbidities And Reducing inEquitieS

Physical Activity to Mitigate PreEclampsia Risk

Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy